<DOC>
	<DOCNO>NCT00945815</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , epratuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cytarabine clofarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving epratuzumab together cytarabine clofarabine may kill cancer cell . PURPOSE : This phase II trial study side effect well give epratuzumab together cytarabine clofarabine work treat patient relapsed refractory acute lymphoblastic leukemia .</brief_summary>
	<brief_title>S0910 Epratuzumab , Cytarabine , Clofarabine Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To test whether complete remission ( CR ) rate ( CR incomplete CR ) adult patient relapse refractory precursor B-cell acute lymphoblastic leukemia sufficiently high treatment cytarabine , clofarabine , epratuzumab warrant investigation . - To estimate frequency severity toxicity associate dose schedule cytarabine , clofarabine , epratuzumab use study . - To investigate , preliminarily , effect laboratory correlate ( minimal post-treatment residual disease ) cytogenetic factor prognosis patient population . ( Not report due limited MRD data ) OUTLINE : This multicenter study . Patients receive cytarabine IV 2 hour day 1-5 , clofarabine IV 1 hour day 2-6 , epratuzumab IV least 1 hour day 7 , 14 , 21 , 28 absence disease progression unacceptable toxicity* . NOTE : * Prophylactic intrathecal methotrexate require patient &lt; 22 year age , recommend ( require ) patient ≥ 22 year age . Blood sample , bone marrow sample , and/or tumor tissue sample may collect laboratory analysis . Patients follow every 3 month 2 year , annually 3 year ( 5 year registration ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm precursor Bcell acute lymphoblastic leukemia ( ALL ) ( non Tcell ) Must evidence disease bone marrow peripheral blood Immunophenotyping blood marrow lymphoblasts must perform determine lineage ( B cell , T cell , mixed B/T cell ) Must ≥ 5 % lymphoblast present blood bone marrow At least 20 % marrow and/or peripheral blood lymphoblast must CD22+ flow cytometry Coexpression myeloid antigen ( CD13 CD33 ) allow Patients extramedullary disease absence bone marrow blood involvement eligible Philadelphia ( Ph ) chromosomenegative disease Patients unknown Ph status cytogenetics FISH unknown BCR/ABL status PCR eligible study registration , must remove study therapy find Ph+ BCR/ABL+ study registration Refractory standard induction regimen include vincristine prednisone highdose cytarabine mitoxantrone OR relapse successful prior induction therapy Any number prior induction therapy number remission achieve allow No M0 acute myeloid leukemia , mixed lineage leukemia , L3 ( Burkitt ) leukemia No active CNS involvement clinical evaluation Patients document history CNS involvement ALL clinical sign symptom consistent CNS involvement ALL must undergo lumbar puncture negative CNS involvement ALL Patients &lt; 22 year age must willing receive prophylactic intrathecal chemotherapy Must register SWOG9007 `` Cytogenetic Studies Leukemia Patients '' ( close 07/01/2010 ) PATIENT CHARACTERISTICS : Zubrod performance status 02 Serum creatinine ≤ 1.0 mg/dL OR glomerular filtration rate &gt; 60 mL/min AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN Not pregnant nursing Fertile patient must use effective contraception ≥ 6 month completion study treatment HIVpositive patient eligible ( discretion investigator ) provide follow criterion meet : No history AIDSdefining condition CD4 cell count &gt; 350/mm³ If antiretroviral agent , must include zidovudine stavudine Willing receive prophylaxis pneumocystis jirovecii pneumonia study therapy ( regardless CD4 cell count ) CD4 cell count &gt; 200/mm³ completion study treatment Prior malignancy ( ALL ) allow provide remission plan treat malignancy time study registration No uncontrolled systemic fungal , bacterial , viral , infection , define exhibit ongoing sign symptom related infection improvement despite appropriate antibiotic treatment No neuropathy ( cranial , motor sensory ) ≥ grade 2 PRIOR CONCURRENT THERAPY : See Disease Characteristics Any number prior therapy allow More 90 day since prior allogeneic bone marrow transplant ( BMT ) No concurrent immunosuppression therapy treatment graftvshost disease ( GVHD ) No acute GVHD ≥ grade 2 , moderate severe limit chronic GVHD , extensive chronic GVHD severity Prior autologous BMT allow No concurrent immunosuppression therapy treatment GVHD More 14 day since prior chemotherapy , investigational agent , major surgery recover Maintenance therapy steroid , vincristine , and/or antimetabolite agent , include limited , mercaptopurine , thioguanine , methotrexate allow Concurrent hydroxyurea reduce WBC reasonable level ( deem treat physician ) allow No prior clofarabine epratuzumab No concurrent cytotoxic therapy investigational therapy No concurrent alternative medication ( e.g. , herbal botanical medication anticancer purpose ) Concurrent participation SWOGS9910 `` Leukemia Centralized Reference Laboratories Tissue Repositories , Ancillary '' allow ( closed 07/01/2010 )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>